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Introduction
Heart failure (HF) is a chronic and debilitating illness that is 
becoming an increasingly important burden on the health care 
system. The American Heart Association (AHA) reported the 
prevalence of HF in American population as 2.6% in 2006, 
with more than 200,000 deaths associated with HF.1 There is 
good evidence that the burden of HF syndrome is increasing 
in the developed countries mainly because of improved sur-
vival and aging population. Approximately 550,000 individu-
als in the United States are diagnosed with HF annually, and 
this number is anticipated to increase to 1.5 million by 2040. 
Recent large epidemiological studies have established that 
at least one-half of patients with HF indeed have preserved 
ejection fraction (EF), termed as heart failure with preserved 
ejection fraction (HFPEF), and that this portion of the 
HF population predominantly consists of women, older age 
group, and people with hypertension and other cardiovascular 
risk factors.2 The prevalence of HFPEF within the popula-
tion varies from 1.14% to 5.5%, depending on the age of the 
population.2 To establish a diagnosis of HF, the contempo-
rary guidelines warrant the presence of symptoms and signs 
specific to HF, and objective evidence of cardiac dysfunction, 
usually by echocardiography. Similarly, three obligatory con-
ditions need to be satisfied to diagnose HFPEF are clinical 
signs and symptoms of HF, normal or near normal systolic 
function, and diastolic dysfunction.3,4
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AbstrAct: Reduced exercise tolerance is an independent predictor of hospital readmission and mortality in patients with heart failure (HF). Exercise 
training for HF patients is well established as an adjunct therapy, and there is sufficient evidence to support the favorable role of exercise training programs 
for HF patients over and above the optimal medical therapy. Some of the documented benefits include improved functional capacity, quality of life (QoL), 
fatigue, and dyspnea. Major trials to assess exercise training in HF have, however, focused on heart failure with reduced ejection fraction (HFREF). At 
least half of the patients presenting with HF have heart failure with preserved ejection fraction (HFPEF) and experience similar symptoms of exercise 
intolerance, dyspnea, and early fatigue, and similar mortality risk and rehospitalization rates. The role of exercise training in the management of HFPEF 
remains less clear. This article provides a brief overview of pathophysiology of reduced exercise tolerance in HFREF and heart failure with preserved ejection 
fraction (HFPEF), and summarizes the evidence and mechanisms by which exercise training can improve symptoms and HF. Clinical and practical aspects 
of exercise training prescription are also discussed.
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Exercise training for HF patients is well established as 
an adjunct therapy. Until only three decades ago, bed rest and 
the restriction of exercise were recommended for people with 
HF. This concept, however, was challenged in 1980s. The first 
study on the effects of exercise in HF was published in 1990,5 
which reported improvement of HF symptoms and physical 
capacity with exercise training, without adverse events. The 
authors concluded that the belief that bed rest was beneficial 
in preserving the hearts of HF patients could no longer be 
accepted. This was followed by further studies that suggest 
that reduced exercise tolerance is in fact an independent pre-
dictor of hospital readmission and mortality in patients with 
HF.6,7 Today, an exercise program is formally recommended 
as an important and safe treatment for HF patients.8–10
The aims of this review are (1) to discuss the clinical and 
practical aspects of exercise training prescription, (2) provide a 
brief account of pathophysiology of reduced exercise tolerance 
in HF, and (3) summarize the evidence and mechanisms by 
which exercise training can improve symptoms of HF in peo-
ple with heart failure with reduced ejection fraction (HFREF) 
and heart failure with preserved ejection fraction (HFPEF). 
Databases including Ovid EMBASE, Ovid MEDLINE, and 
PubMed were searched for terms (heart failure, diastolic heart 
failure, heart failure with normal ejection fraction, heart fail-
ure with preserved ejection fraction, exercise training, cardiac 
rehabilitation) up to December 2014.
exercise Prescription in HF Patients
Most contemporary guidelines generally suggest an aerobic 
activity of at least 30 minutes for five or more days per week. 
There is a great variation between the exercise programs and the 
level of intensity in HF trials. Clinically, an intensity range of 
70–80% of peak heart rate (HR) is usually deemed as sufficient 
when a symptom-limited exercise protocol is utilized. The rating 
of perceived exertion (RPE) has also been used as an indicator 
for work intensity and as a tool in the prescription of exercise 
training intensity.11 The RPE score has been shown to be reli-
able and valid, and it has a moderate to high correlation (r range, 
0.57–0.89) with respiratory variables, HR, and blood lactate in 
healthy men.12 In HF, patients’ RPE should be considered as 
an adjunct to a training intensity determined by the percentage 
of VO2peak (peak oxygen consumption; as a measure of exer-
cise capacity), HR, blood pressure, and symptom monitoring 
because the RPE determined during graded cardiopulmonary 
exercise testing may not consistently translate to the same inten-
sity as that during exercise training, and a certain percentage of 
patients are unable to reliably use the RPE scale. Since during 
exercise, ratings of fatigue and dyspnea are often differently per-
ceived, both symptoms should be monitored separately.10,12
Although there is no consensus as to which methods 
and exercise intensities are better for the treatment of HF 
patients, the sub-maximum seems to offer a better safety/ 
efficiency balance.13 The most recent Australian guidelines 
recom mend moderate-intensity training at 40–70% VO2peak 
with a graded increment in duration of exercise, initially from 
10 to 15 minutes and increasing to 45–60 minutes per session.14
Studies have also looked into added utility of higher 
intensity exercise when compared to low–moderate-intensity 
levels, and have been postulated to have further beneficial 
effects on VO2peak, left ventricular (LV) remodeling, endothe-
lial function, as well as mitochondrial function. Patwala et al.15 
have shown significant added improvement in VO2peak after 
a high-intensity training program that comprised 80–90% of 
peak HR. This additional benefit was more than that obtained 
after cardiac resynchronization therapy (CRT).
Although aerobic training (AT) remains the frontline 
of recommendations, resistance training has been associated 
with increased muscle power, endurance, and peripheral blood 
flow.16,17 Levinger et al.18 examined the effects of resistance 
training vs. usual activity in patients with HF and found 
modest improvements in resting EF despite unchanged LV 
volumes. A similar study examined the effect of resistance 
training on the capacity to perform activities of daily living 
(ADLs) and quality of life (QoL) in individuals with high 
number of metabolic risk factors (HiMF) compared with indi-
viduals with a low number of metabolic risk factors (LoMF).19 
Resistance training improved muscle strength and the capac-
ity to perform ADLs in individuals with HiMF and LoMF. 
Resistance training improved QoL for the HiMF group, and 
this result was independent of changes in body fat content or 
aerobic power. A recent systemic review to evaluate resistance 
training, either alone or as an adjunct to AT, for improving 
cardiac function, exercise capacity, and QoL in people with 
HF20 concluded that resistance training increased six-minute 
walk distance compared to no training, but had no other bene-
fits on cardiac function, exercise capacity, or QoL if used alone 
or as an adjunct to AT in people with chronic HF.
Similarly, another recent study compared the com-
bined aerobic and resistance training (ART) with an AT in 
a population of obese type 2 diabetic patients and metabolic 
syndrome. A total of 47 patients were randomly assigned to 
aerobic (27 patients) or aerobic plus resistance (20 patients) 
exercise trainings. Although this study did not particularly 
focus HF patients, it did show the difference in effects on the 
related outcomes. Both exercise programs equally improved 
body weight. Mean blood pressure (AT: −3.6 mmHg vs. ART: 
+0.6 mmHg, P , 0.05) and endothelin-1 (ET-1) incremen-
tal areas during walking test (AT: −11% vs. ART: +30%, 
P , 0.0001) decreased after AT and increased after ART. 
Adiponectin levels increased by 54% after AT, while decreased 
by 13% after ART (P , 0.0001) and matrix metalloprotei-
nase-2 (MMP-2), tumor necrosis factor-alpha (TNF-α), 
and monocyte chemoattractant protein-1 (MCP-1) levels sig-
nificantly decreased in AT, while increased in the ART group. 
This study suggested that ART, as compared with AT, simi-
larly enhanced body weight loss but exerted less positive effects 
on insulin sensitivity and endothelial factors, adipokines, and 
proinflammatory marker release.21 Beckers et al also reported 
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that when comparing with RT alone, six months of ART 
resulted in a greater improvement of submaximal exercise 
capacity, upper extremity muscle strength, and cardiac 
symptoms.16
Despite the HF being a condition affecting primarily the 
elderly population, most of the studies have excluded patients 
with an age .70 years. Wisloff et al.22 studied 27 patients with 
stable post-infarction HF with a mean age of 75.5 ± 11.1 years 
who were randomized to either moderate continuous training 
(MCT) (70% of peak HR) or aerobic interval training (AIT) 
(95% of peak HR) three times per week for 12 weeks or to a 
control group. The major finding of this study was that AIT 
was superior to MCT in patients with post-infarction HF with 
regard to LV remodeling reversal, aerobic capacity, endothe-
lial function, and QoL. It demonstrated that high-intensity 
training relative to the individual’s maximal oxygen uptake is 
feasible even in elderly patients.
In summary, although there is no expert consensus on 
the mode of exercise, combined resistance and AT is likely 
to optimize the benefits by acting on both the central and 
peripheral pathways. It is superior to aerobic exercise alone for 
improving QoL, endurance, and muscle strength.16 A train-
ing approach to combined ART can minimize hemodynamic 
burden by focusing on small muscle groups and maximizing 
peripheral adaptations.14 The benefits of resistance training 
in isolation are not clear. Any recommendation for exercise 
training in HF should be based on the particular pathology 
of the patient, the individual’s response to exercise (includ-
ing HR, blood pressure, symptoms, and perceived exertion), 
and measurements obtained during cardiopulmonary exercise 
testing. Additionally, patient’s individual status, including 
current medication, risk factor profile, behavioral characteris-
tics, personal goals, and exercise preferences, should be taken 
into consideration.10 Absolute and relative contraindications 
for exercise training in HF patients are outlined in Table 1.
Pathophysiology of exercise Intolerance in HF
Mechanisms involving the cellular metabolism and intracel-
lular energy transfer in cardiac as well as skeletal muscle, sym-
pathetic neural activation, and inflammatory cytokines, all 
possibly contribute to the development of exercise intolerance 
in HF (Table 2). Although central factors, such as EF or car-
diac output, do play a role, it is mostly peripheral factors that 
are responsible for the reduction in exercise capacity.23
central pathophysiology and exercise intolerance. 
Cardiac causes. 
1. LV dysfunction is characterized by a decrease in EF 
from the normal range of 60–70% to less than 45%.8 
This is followed by a reduction in stroke volume (SV)24 
and cardiac output, first during exercise and then subse-
quently at rest.25,26 Although abnormalities in the central 
hemodynamic response have been described in patients 
with HF, there remains the paradox that measures of 
resting ventricular function, such as EF, demonstrate a 
poor correlation with exercise capacity.27–29 However, an 
improvement in exercise capacity after CRT may be in 
part because of the improvement in systolic function.15 
The response to exercise in the patient with systolic HF is 
characterized by inadequate LV shortening with increases 
in end-systolic and end-diastolic volumes. Diastolic dys-
function, on the other hand, is characterized by impaired 
LV distensibility during exercise, resulting in a rapid rise 
in LV diastolic pressure and pulmonary capillary wedge 
pressure that result in symptoms of dyspnea.29
2. Reduced cardiac output because of a low SV as well as a 
lower HR reserve.30
3. Elevated LV pressure can lead to pulmonary congestion, 
particularly on exercise, which may result in secondary 
pulmonary hypertension with time. This in turn may 
affect the right ventricular function.4
Table 1. Contraindications for exercise training in hF14.
abSolUTE ConTRaindiCaTionS RElaTivE ConTRaindiCaTionS
Progressive worsening of exercise tolerance or dyspnea at rest or on  
exertion over previous 3–5 days
$2 kg increase in body mass over previous 1–3 days
Significant ischemia at low exercise intensities (,2 Mets, or ,50 W) Concurrent continuous or intermittent dobutamine therapy
Uncontrolled diabetes decrease in systolic blood pressure with exercise
acute systemic illness or fever new york heart association Functional Class iV
recent embolism Complex ventricular arrhythmia at rest or appearing with exertion
thrombophlebitis supine resting heart rate $100 bpm
active pericarditis or myocarditis Pre-existing comorbidities
severe aortic stenosis Moderate aortic stenosis
regurgitant valvular heart disease requiring surgery BP .180/110 mmhg (evaluated on a case by case basis)
Myocardial infarction within previous 3 weeks
New onset atrial fibrillation
resting heart rate .120 bpm
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4. Functional mitral regurgitation (MR) can be a conse-
quence of dilated cardiomyopathy or papillary muscle 
dysfunction leading to reduced SV.31,32
5. Reduced chronotropic reserve in HF, ie, an inability to 
increase the HR in response to exercise, will lead to fail-
ure to increase cardiac output and result in dyspnea dur-
ing exercise.33
Respiratory causes. 
1. Exaggerated minute ventilation relative to carbon diox-
ide (CO2) production – irrespective of the presence of 
pulmonary congestion, exercise in HF patients will result 
in a marked rise in minute ventilation, out of proportion 
to the respiratory rate-dependent raised CO2 production, 
contributing to potential significant pulmonary ventila-
tion/perfusion mismatch.34,35
2. Structural abnormalities such as fibrosis and vascular 
injury, related to pulmonary hypertension and venous 
congestion, have been seen in HF.35,36
3. Alveolar edema secondary to pulmonary congestion.35,36
4. Poor inspiratory muscle performance is associated with 
dyspnea, poor exercise tolerance, and poor functional sta-
tus in HF. Inspiratory muscle training has been observed 
to improve dyspnea, QoL, peripheral muscle and periph-
eral blood flow, HR, respiratory rate, VO2peak, and sev-
eral indices of cardiac performance.37
Peripheral pathophysiology and exercise intolerance. 
While some studies claimed that poor exercise capacity in 
patients with HF is caused by a reduction in EF38 and cardiac 
output,39,40 most researchers have suggested that changes in the 
periphery are the main contributors to poor exercise capacity in 
these patients. These alterations include an increase in peripheral 
vascular resistance, changes in skeletal muscle metabolism, and 
reduction in skeletal muscle blood flow, mass, and strength.41–48
Skeletal muscle causes. 
1. A reduced skeletal muscle mass has been seen in HF 
patients,49 which in turn has been associated with reduced 
exercise capacity.46
2. An alteration in fiber type from type I to type IIb has 
been seen in HF patients. These type IIb fibers have fast 
vs. slow twitching and glycolytic vs. oxidative properties 
and affect aerobic exercise capacity adversely.50
3. Decreased oxidative metabolism and adenosine triphos-
phate (ATP) production – With maximal exercise testing, 
the HF patients typically report leg fatigue. This fatigue 
is associated with increased lactate release from the legs, 
evidence supportive of skeletal muscle dysfunction. Lac-
tate levels correlate closely with maximal exercise capac-
ity, suggesting a link between muscle dysfunction and 
exercise intolerance in HF. One study suggests that nei-
ther reduction in muscle oxidative capacity nor reduction 
in capillary density appears to be the cause of exercise 
limitation in patients with HF.51 In this study, VO2peak 
was determined in 14 HF patients and 8 healthy sed-
entary similar-age controls. Muscle samples were ana-
lyzed for mitochondrial ATP production rate (MAPR), 
oxidative and glycolytic enzyme activity, fiber size and 
type, and capillary density. HF patients demonstrated a 
lower VO2peak (15.1 ± 1.1 vs. 28.1 ± 2.3 mL⋅kg−1⋅min−1, 
P , 0.001) and capillary to fiber ratio (1.09 ± 0.05 vs. 
1.40 ± 0.04, P , 0.001) when compared with controls. 
However, there was no difference in capillary density 
(capillaries per square millimeter) across any of the fiber 
types. Measurements of MAPR and oxidative enzyme 
activity suggested no difference in muscle oxidative 
capacity between the groups. Based on these findings, the 
authors hypothesized that the low VO2peak observed in 
HF patients may be the result of fiber atrophy and pos-
sibly impaired activation of oxidative phosphorylation.
Table 2. Pathophysiological causes of exercise intolerance in hF and improvement in these pathologies that is associated with exercise.
PaTHoPHYSiologY imPRovEmEnT aSSoCiaTEd wiTH ExERCiSE
Central causes
• left ventricular dysfunction leading to reduced stroke volume and  
cardiac output
•	 reduce chronotropic reserve
•	 Pulmonary congestion secondary to lV dysfunction
•	 Functional mitral regurgitation
•	 exaggerated minute ventilation relative to carbon dioxide production
•	 Pulmonary structural abnormalities
•	 Poor inspiratory muscle performance
•	 improvement of cardiac output at peak exercise level
•	 reduction of resting left ventricular end-diastolic diameter
•	 reduced left ventricular diastolic wall stress
•	 30% increase in Vo2peak
•	 improved functional capacity in people with dilated cardiomyopathy 
and diastolic dysfunction
•	 inspiratory muscle training improves symptoms, Vo2peak and  
cardiac performance
Peripheral causes
•	 reduced skeletal mass
•	 Alteration in skeletal fiber from type 1 to type IIb
•	 decrease skeletal oxidative metabolism and atP production
•	 endothelial dysfunction
•	 dysregulated neurohumoral system
•	 Production of inflammatory cytokines
•	 improved skeletal mitochondrial load and oxidative metabolism
•	 Reverse-shift from type IIb skeletal muscle fibers to type I
•	 Improved peripheral blood flow with more efficient energy delivery
•	 improvement of endothelial dysfunction
•	 reduced nadPh and ros generation
•	 reduced sympathetic activity
•	 reduced production of tnF-α and il-6
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Studies have shown that patients who suffer from 
moderate–severe LV impairment have a reduced mitochon-
drial density and oxidative enzyme activity (citrate syntheses 
and β-hydroxyacyl CoA dehydrogenase).52–56 Drexler et al.57 
found a decrease in both surface density and volume den-
sity of mitochondrial cristae (20% and 17%, respectively) in 
patients with severe CHF. These changes were consistent with 
a reduced oxidative capacity of skeletal muscle, from ∼60% 
of mitochondria in normal subjects to ∼17% of mitochondria 
in HF patients. As a result of reduction in oxidative enzyme 
activity, carbohydrate would be utilized as a source of energy 
instead of fat, which may result in early anaerobic metabo-
lism and fatigue.56 Kemp et al.58 found that the non-oxidative 
ATP cost of work had increased by 150% during exercise in 
HF patients and was followed by glycogenolytic production, 
while there was a reduction in the oxidative cost by 26%. Fur-
thermore, they reported a decrement in cytosolic pH with an 
increase in glycogenolysis during exercise when compared to 
the control group.
Both activity of oxidative enzymes and mitochondrial 
cristae surface density showed significant correlation with ven-
tilator threshold and VO2peak in patients with HF (r between 
0.56 and 0.82).57,59–63 These findings suggest that a reduction 
in mitochondria number and/or its inability to utilize the oxy-
gen delivered (secondary to a decrease in oxidative enzymes) 
may have contributed to the reduction in oxidative capacity, 
leading to an early onset of anaerobic metabolism and lactate 
production.55,60,64,65
Other peripheral causes. Endothelial dysfunction (associ-
ated with lower nitric oxide (NO) and impaired vasodilatory 
response to shear stress) and defects in neurohumoral system 
affecting sympathetic and parasympathetic activities, and 
proinflammatory cytokines, all have been associated with 
reduced exercise capacity in HF patients.41–48
Studies in the past decade have suggested that specific 
alterations in HFPEF consist of cardiomyocyte hypertrophy 
and interstitial fibrosis, whereas functional changes include 
incomplete relaxation of myocardial strips and increased car-
diomyocyte stiffness. Furthermore, abnormal intramyocardial 
signaling evident from endothelial cells expressing adhesion 
molecules, inflammatory cells secreting profibrotic transform-
ing growth factor β (TGF-β), and oxidative stress increas-
ing nitrotyrosine content are also seen in this population.66 
In HFPEF, comorbidities contribute to a systemic inflam-
matory state, which induces oxidative stress in the coronary 
microvascular endothelium. This reduces myocardial NO bio-
availability and leads to reduced protein kinase G activity in 
cardiomyocytes, which therefore become stiff and hypertro-
phied. This differs from myocardial remodeling in HFREF, 
which is driven by cardiomyocyte death because of oxidative 
stress originating in the cardiomyocytes as a result of isch-
emia, infection, or toxicity.66
HFPeF and exercise intolerance. It has been postu-
lated that patients with HFPEF have concomitant arterial 
stiffening, contributing to increased LV afterload and 
alterations of systolic and diastolic functions, particularly dur-
ing exercise.67,68 The increased afterload consequently affects 
the diastolic filling, again particularly during exercise when a 
more efficient diastolic filling pressure is required,29 and atrial 
function becomes a significant determinant of LV filling, thus 
leading to increased LV filling pressure.69–71 Ultimately, it 
is the combined relationship between central and peripheral 
mechanisms, as detailed above, that forms the global ventricu-
lar–vascular interaction, and importantly, it is this relationship 
during exercise that contributes to HF symptoms.72 Owing 
to the known beneficial effects on peripheral vascular resis-
tance, arterial stiffening, and abnormalities of skeletal muscle 
metabolism in the HFPEF syndrome, exercise training pres-
ents a viable management and therapeutic tool.72
benefits of exercise in HF
Many exercise benefits for HF patients have been docu-
mented, such as improvements in physical capacity (an 
increase in 10–30% of the maximum physical capacity),73,74 
QoL,75 endothelial dysfunction,76 circulating catecholamine 
levels,77 morbidity, and hospital admissions.78 These above-
mentioned changes lead to increased overall exercise capacity 
with a lower required HR. Exercise training is now widely 
used as an adjunct therapy for the stable HF patients79 with 
class 1 recommendation by the American College of Cardiol-
ogy (ACC) and the AHA.80
Most HF trials have used moderate/high-intensity 
exercises (70–80% of peak HR). A lower intensity program of 
40–50% VO2peak has also been shown to improve the exercise 
capacity.75 The recent “Heart Failure – A Controlled Trial 
Investigating Outcomes of exercise TraiNing” (HF-ACTION) 
trial, a multicentre, randomized controlled trial looking at 2,331 
HF patients with EF #35%, and New York Heart Association 
functional classes II–IV showed a nonsig nificant reduction 
in the primary combined end-point of all-cause mortality or 
hospital stay (HR: 0.93; P = 0.13) after a moderate-intensity 
training followed by home-based training with a total of 
30 months median follow-up. Furthermore, no difference in 
mortality was observed between the exercise and control arms 
(16% vs. 17%). Significant improvement in VO2peak was, how-
ever, noted in the exercise group (0.6 vs. 0.2 mL/kg/minute). 
It was, however, noted that only approximately 40% of the 
exercise group reported a training reaching the prescribed dura-
tion of 1.5 hours/week for the first three months, which would 
likely account for only modest increase in VO2peak, impacting 
on statistical differences in outcomes between the exercise and 
control arms.81 As far as the adverse events related to exercise 
in HF patients are concerned, HF-ACTION showed no differ-
ence during the entire study period.81
role of exercise in HFPeF. Major trials to assess 
exercise training in HF have focused on HFREF. Since 
the patients with HFPEF also experience exercise intoler-
ance, dyspnea, early fatigue, and similar mortality risk and 
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rehospitalization rates, a case can be made for exercise to be 
part of the management of people with HFPEF.79
Gary et al.82 have evaluated effects of exercise training 
on elderly women with HFPEF. A total of 32 women with 
New York Heart Association classes II and III HFPEF (LV 
EF .45% and symptoms of dyspnea or fatigue) were random-
ized into a 12-week home-based, low-to-moderate-intensity 
(40% and 60%, respectively) exercise and education program 
(intervention) or only education program (control). The inter-
vention group improved in the six-minute walk test (+20% 
vs. −11%). Improved QoL and depression were also reported. 
Similar findings were demonstrated by Smart et al.83 among 
18 patients with HFPEF who improved their QoL and exer-
cise capacity by 30%, although without a change in diastolic 
dysfunction. Kitzman et al.84 randomized 53 patients with 
HFPEF to either a three days per week exercise program or 
control group. Increased exercise capacity and physical score 
(measured on Minnesota Living with Heart Failure Question-
naire) were seen after 16 weeks of training, while no change 
was observed in neuroendocrine or LV function.
Diabetes is common in HFPEF patients and is associated 
with increased ventricular stiffness. Subclinical diastolic dys-
function without HFPEF is a common complication of type 
2 diabetes mellitus (T2DM) that is independently associated 
with poor cardiovascular outcomes.85 To date, no study has 
demonstrated the ability to alter the progression of diastolic 
dysfunction in diabetes. Hare et al have studied the impact of 
an exercise-lifestyle intervention on diastolic dysfunction in 
patients with T2DM.85 In all, 223 outpatients with T2DM 
were randomized to supervised exercise-lifestyle interven-
tion or usual care. Patients receiving the intervention were 
randomized to a two-stage supervised exercise program that 
comprised an initial four-week gym-based exercise program of 
two 1-hour exercise sessions per week, supervised by an exer-
cise physiologist, with a further 30 minutes of home-based 
exercise. Each individualized program sought to provide at 
least moderate exertion using a combination of both aerobic 
and resistance exercises. The subsequent home-based program 
was supported by telephone counseling, with an emphasis 
on maintenance and improvement. This contact was initially 
weekly and then once every two weeks for three months, with 
monthly follow-up thereafter. Patients underwent echocardio-
graphic assessment of diastolic function, metabolic and clinical 
evaluations at baseline and three years. Diastolic dysfunction 
was present in 50% of patients at baseline and 54% of patients 
at three years, with no difference between usual care and inter-
vention groups (60% vs. 48%, P = 0.10). Abnormal diastolic 
function at the final visit was independently associated with 
older age and a decrease in VO2peak over time (P , 0.05). In 
a sub-analysis restricted to those who finished the full three-
year follow-up, control subjects were independently associated 
with diastolic dysfunction at three years (β = 0.90, OR = 2.46, 
P = 0.034), with the only other independent correlate being 
older age (β = 0.05, OR = 1.06, P = 0.019). In this study, three 
years of exercise-based lifestyle intervention was not effective 
in reducing progression of subclinical diastolic dysfunction in 
patients with T2DM.
A recent systematic review to assess the effect of exercise 
training in patients with HFPEF suggested benefit in terms 
of enhancements in exercise capacity and health-related QoL, 
and the exercise training appeared to be safe.72 The review 
included studies for a total of 228 individuals, and the com-
bined duration of exercise programs and follow-up ranged 
from 12 to 24 weeks. No deaths, hospital admissions, or serious 
adverse events were observed during or immediately following 
exercise training. Compared to control, the change in exercise 
capacity at follow-up was higher with exercise training. There 
was evidence of a larger gain in health-related QoL with exer-
cise training. The largest study included in the review showed 
some evidence of improvement in the E/e′ ratio with exercise 
training, but this was not confirmed in the other studies; E/A 
ratios were not changed. Thus, despite the benefit of improved 
exercise capacity and QoL, the impact on diastolic function 
remains unclear. Further trials should provide data on long-
term effects, prognostic relevance, and cost-effectiveness.72
cardiac effects. Exercise training at submaximal levels 
in HF has no effect on cardiac output86–88 and slight improve-
ment at peak exercise levels.77,87 Hambrecht et al.77, on the other 
hand, demonstrated reductions in resting left ventricular end-
diastolic diameter (LVEDD), suggesting a training-induced 
reverse remodeling. Furthermore, reduced LV diastolic wall 
stress even at low–moderate workload (50% VO2peak) has 
been seen along with a 30% increase in VO2peak after two 
months.89 Belardinelli et al.90 demonstrated improvement in 
the functional capacity of people with dilated cardiomyopa-
thy and diastolic dysfunction with training. This improve-
ment was, however, limited to people with delayed relaxation. 
Restrictive cardiomyopathy in this study was associated with 
a worse prognosis.
Peripheral effects. Reversible peripheral abnormalities in 
HF patients include changes in skeletal muscle and vasomotor 
tone. Exercise training can improve mitochondrial load with 
improved oxidative metabolism.86,91,92 A reverse-shift from 
type IIb skeletal muscle fibers to type I has also been demon-
strated, which is associated with improved exercise capacity.61 
An improved peripheral blood flow and more efficient oxygen 
delivery have also been seen after exercise training.88 A ben-
eficial effect on endothelial dysfunction, likely NO mediated 
as suggested by Hambrecht et al.77, and endothelium-depen-
dent peripheral blood flow has been associated with improved 
VO2peak.76
Furthermore, messenger ribonucleic acid expression of 
nicotinamide adenine dinucleotide phosphate (NADPH) oxi-
dase activity and reactive oxygen species (ROS) generation 
responsible for angiotensin II-mediated vasoconstriction has 
been seen to reduce with exercise.93,94 A decrease in sympa-
thetic activity has also been demonstrated.95–98 Reduced levels 
of the inflammatory cytokines TNF-α and interleukin-6 
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(IL-6) after training are again associated with an improved 
exercise capacity.99,100
exercise training in HF Patients with Artificial 
devices
Exercise training in patients with implantable cardiac devices 
(ICDs/CRT) has been reported to improve QoL and exercise 
capacity and seems to be safe.101 Furthermore, it can also have a 
positive effect on anxiety in ICD patients and can reduce the 
fear of exercise.102–104 Care should, however, be taken for the 
maximum training HR not to exceed the ICD-intervention 
HR to avoid any inappropriate shocks. Avoiding a physical 
trauma to the device, including activities with pronounced 
arm/shoulder movements, is also sensible.105 It is recom-
mended that exercise HR reach no higher than 10–15 beats 
below the ICD tachycardia threshold. Furthermore, upper 
body resistance exercise should be restricted until six weeks 
after implantation to prevent dislodgement of newly implanted 
device leads and healing of the defibrillator site.14
Potential risks Associated with exercise Therapy  
in HF
Exercise training in HF patients is considered safe. Sudden 
cardiac death (SCD) during exercise is rare in apparently 
healthy individuals. Individuals with cardiac disease seem to 
be at a higher risk than healthy individuals. The incidence of 
major cardiovascular complications during outpatient cardiac 
exercise programs has been estimated to be 1 in 60,000 
participant-hours.106 Myocardial infarction is another risk 
associated with participation in exercise and is more likely 
to occur than SCD. It is highly recommended that a patient 
should undergo a symptom-limited graded exercise test prior to 
commencement of exercise training. This test, along with the 
clinical assessment and measurement of LV function, is used 
to determine the safety to commence an unmonitored exercise 
program by excluding myocardial ischemia, determining isch-
emic thresholds for those in whom complete control of isch-
emia is not possible, excluding exercise-induced ventricular 
tachycardia, determining ventricular rate control in patients 
with atrial fibrillation, assessing functional capacity, and mea-
suring both work rates and HRs at submaximal and maximal 
levels of exercise.14 The health professional should be capable 
of monitoring, managing, and reporting signs and symptoms 
of worsening HF, excessive shortness of breath or fatigue, and 
vasovagal signs and symptoms, including bradycardia, exces-
sive sweating, dizziness, confusion, and acute hypotension 
that may lead to syncope. All adverse events related to exercise 
must be reported promptly to the primary care medical prac-
titioner or emergency medical personnel.14
conclusion
Exercise intolerance through various mechanisms is the major 
incapacitating issue in HF patients, and exercise training 
programs have shown to improve functional capacity, QoL, 
dyspnea, as well as HF-related lassitude. Clinical trials have 
demonstrated a multitude of benefits affecting exercise capac-
ity, metabolic function, vascular tone, cytokine production, and 
neural activation. Tailored exercise prescription for the modal-
ity and intensity, by assessing and interpreting clinical infor-
mation and applying the principles of training to develop an 
appropriate regimen, is important to ensure efficiency and safety 
of the program. Regular exercise results in a modest reduction 
in risk for clinical events, with even greater benefits likely in 
patients who adhere to a higher volume of exercise. The impact 
of exercise training on diastolic function, however, remains less 
clear as there is inadequate information of long-term outcomes 
in HFPEF patients, including mortality, hospitalization, and 
cost-effectiveness. Nevertheless, it appears safe, and further tri-
als in objectively defined HFPEF populations are required.
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